Main India Herceptin patent still valid but procedural lapses hit 'divisionals'
This article was originally published in Scrip
Executive Summary
India has clarified that Roche's patent applications concerning the anticancer, Herceptin (trastuzumab), were not in fact revoked but considered "withdrawn" in one instance and "abandoned" in another, after the Swiss multinational failed to comply with procedural requirements under Indian regulations.